{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 20 of 122', 'Demonstrating a beneficial effect on quality of life and health utility of treatment with', 'AR101 will be informative to certain treatment decision-makers, including payers. However,', 'assessment of HRQOL can be complex for infrequent episodic conditions such as peanut', 'allergy. Food allergy HRQOL is unusual because it is not characterized by daily or frequent', 'symptoms that would allow patients to perceive changes in their health status; rather, it is', 'characterized by beliefs and expectations about the risk of anaphylaxis occurring due to', 'unpredictable accidental exposures and the expected benefits of interventions that reduce this', 'risk. Experiencing an HRQOL benefit from treatment is entirely dependent on patient (and', 'parent/caregiver) knowledge that they have been receiving an active treatment and have been', 'successfully desensitized to the food allergen in question.', 'An open-label study of HRQOL of patients on standard of care alone and their', 'parents/caregivers will enable a more real-world comparison of treatments than a blinded', 'study. In a blinded study setting, patients in both treatment groups would be required to', 'follow the same study site visit schedule, which is necessarily frequent during up-dosing with', 'food allergens to safely achieve the desired level of desensitization. As this visit frequency is', 'much higher than real-world standard of care practice, it could significantly affect patient and', 'parent/caregiver responses to questionnaires. In an open-label study, the visit schedule for', 'patients receiving standard of care alone can be less frequent and would more closely align', 'with real-world standard of care practice. Therefore, an open-label study design is preferred', 'when assessing the real-world impact of AR101 treatment versus standard of care on', 'HRQOL.', 'Additionally, previous studies have shown that the DBPCFC also influences HRQOL,', \"because the information it imparts helps reduce uncertainty about the status of the patient's\", 'allergy and may reduce anxiety about their ability to manage an allergic reaction arising from', 'accidental exposure (Franxman, 2015; Soller, 2014). As a DBPCFC is not part of the', 'diagnostic pathway for peanut allergy, the ARC009 eligibility criteria include a range of', 'other relevant clinical and patient factors. However, all subjects will have an open-label food', 'challenge (OLFC) approximately 12 months after randomization to study treatment (AR10', 'or standard of care alone). Because approximately 20% of children are estimated to outgrow', 'their peanut allergy and periodic re-evaluations are recommended (Sampson, 2014;', 'Skolnick, 2001), the OLFC results will be used to confirm peanut allergy for subjects who', 'complete 18 months of standard of care alone as part of the eligibility to receive AR101 in an', 'open-label follow-on study.', 'HRQOL outcomes have been assessed in randomized, double-blind, placebo-controlled', 'studies of AR101, including ARC003 (PALISADE), ARC007 (RAMSES), and ARC010', '(ARTEMIS), and in their open-label follow-on studies. However, ARC009 is anticipated to', 'yield more meaningful HRQOL results and to better reflect the true-life patient/parent', '(caregiver) experience of AR101 treatment in combination with standard of care compared', 'with standard of care alone, and thus will provide relevant HRQOL evidence for treatment', 'decision-makers.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 21 of 122', '2', 'STUDY OBJECTIVES', '2.1', 'Primary Objective', 'To assess proxy- and self-reported disease-specific HRQOL of peanut-allergic', 'subjects aged 4 to 17 years, inclusive, receiving AR101 in combination with standard', 'of care versus standard of care alone for approximately 18 months', '2.2', 'Secondary Objectives', 'Safety and tolerability of AR10', 'To characterize changes over the course of the study in the following:', 'Disease-specific HRQOL of parents/caregivers', 'Relationship between clinical efficacy of AR101 (change in level of sensitization to', 'peanut allergen) and HRQOL of subjects and parents/caregivers', '2.3', 'Exploratory Objectives', 'To assess the following:', 'Self-reported assessments of control and confidence; reassurance, worry, and severity', 'of allergic reactions based on food challenge outcomes; and overall HRQOL', 'Changes in nondisease-specific measures of HRQOL, anxiety, and depression in', 'subjects and parents/caregivers', 'Health state utility estimates for economic analysis', 'Changes in peanut skin prick test (SPT) mean wheal diameters associated with', 'AR101 treatment', 'Changes in control of pre-existing concomitant atopic disease (asthma, allergic', 'rhinitis, atopic dermatitis)', 'Relationship between basophil activation, clinical efficacy of AR101, and changes in', 'HRQOL', 'AR101 treatment experience among subjects and parents/caregivers', '3', 'INVESTIGATIONAL PLAN', '3.1', 'Overall Study Design and Plan: Description', 'This is a phase 3b, randomized, open-label, European study of the HRQOL of AR101 in', 'combination with standard of care (AR101 herein) compared with standard of care alone in', 'approximately 200 peanut-allergic subjects aged 4 to 17 years, inclusive. Standard of care', 'includes avoidance of peanuts/peanut-containing foods, and education on recognition and', 'management of allergy symptoms and appropriate use of rescue medications (eg, epinephrine', 'auto-injectors). HRQOL of parents/caregivers will also be assessed. The safety and', 'tolerability of AR101 will be evaluated.']\n\n###\n\n", "completion": "END"}